Left Atrial Appendage Management with the Watchman Device during Hybrid Ablation of Atrial Fibrillation.

ABSTRACT:

Background

In the recent ESC/EACTS guidelines, left atrial appendage (LAA) occlusion or exclusion in patients undergoing (thoracoscopic) atrial fibrillation (AF) ablation surgery is recommended. The Watchman device (WD, Boston Scientific, Minnesota) has proved to reduce the risk of thromboembolic events by closing of the LAA, yet no data exist on WD implantation during surgical AF ablation. The objective is to determine if WD implantation is safe and feasible in a hybrid AF ablation setting (i.e., combination of thoracoscopic epicardial surgical and endocardial catheter ablation) and could become subject of further testing to serve as a bail-out in cases in which surgical LAA occlusion methods cannot be applied, due to, for example, severe adhesions.

Methods

In this prospect

SUBMITTER: Vroomen M 

PROVIDER: S-EPMC6739757 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature